Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy Products
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...
View HTML
Toggle Summary RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...
View HTML
Toggle Summary RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers’ Diarrhea
Aemcolo ®  (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestine Aemcolo ® is approved by the FDA for the treatment of travelers’ diarrhea, and is covered by a robust U.S. patent portfolio which, together with the U.S. ...
View HTML
Toggle Summary RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
Key Highlights: U.S. FDA approval of Talicia ® for the treatment of Helicobacter pylori infection in adults   Strategic partnership with Cosmo Pharmaceuticals , including investment of $36.3 million and exclusive rights to commercialize Aemcolo ® in the U.S. ...
View HTML
Toggle Summary Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML
Toggle Summary RedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML
Toggle Summary RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults
RedHill plans to launch Talicia ® 1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for  H. pylori infection annually Talicia ® is the first and only FDA approved rifabutin-based H. ...
View HTML
Toggle Summary RedHill Biopharma to Present at the BIO-Europe 2019 Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML